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ABSTRACT
MULTIPURPOSE TENOFOVIR DISOPROXIL FUMARATE ELECTROSPUN
FIBERS FOR THE PREVENTION OF HIV-1 AND HSV-2 INFECTIONS
Kevin Tyo
July 13, 2016
Sexually transmitted infections affect hundreds of millions of worldwide. Both
human immunodeficiency virus (HIV-1 and -2) and herpes simplex virus-2 (HSV2) remain incurable, urging the development of new prevention strategies. While
current prophylactic technologies are dependent on strict user adherence to
achieve efficacy, there is a dearth of delivery vehicles that provide discreet and
convenient administration, combined with prolonged-delivery of active agents.
To address these needs, we created electrospun fibers (EFs) comprised of FDAapproved polymers, poly(lactic-co-glycolic acid) (PLGA) and poly(DL-lactide-coε-caprolactone) (PLCL), to provide sustained-release and in vitro protection
against HIV-1 and HSV-2. PLGA and PLCL EFs, incorporating the antiretroviral,
tenofovir disoproxil fumarate (TDF), exhibited sustained-release for up to 4
weeks, and provided complete in vitro protection against HSV-2 and HIV-1 for 24
hr and 2 wk, respectively. In vitro tests confirmed the safety of these fibers in
vaginal and cervical cells, highlighting the potential of polymeric EFs as
multipurpose next-generation drug delivery vehicles.
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BACKGROUND AND INTRODUCTION
Sexually transmitted infections (STIs) are a global health challenge, with
over one million new cases of STIs reported daily. Over 530 and 36 million
people globally are infected by herpes simplex virus type-2 (HSV-2) and human
immunodeficiency virus (HIV), respectively [1]. Compounding these statistics,
HSV-2 infection has been shown to significantly enhance HIV infection by as
much as 2 to 7-fold [2, 3]. Furthermore, co-infected individuals harbor higher
concentrations of both viruses relative to individuals with only one infection [3].
Despite the existence of multiple strategies to prevent STIs, no cure exists for
these diseases, and rates of infection among particular demographics remain
high [4, 5].
The first known incidence of HIV infection originated in the late 1950s in
what is today known as the Democratic Republic of the Congo [6]. The general
consensus of scientists is that HIV originated from cross-species contamination
of simian immunodeficiency viruses (SIVs), which normally infect primates. The
first known cases of the current HIV pandemic in the United States date back to
1981, where previously healthy homosexual men began suffering and dying from
opportunistic infections [7]. At first this emerging disease, designated Acquired
Immune Deficiency Syndrome (AIDS) was widely believed to only affect
homosexuals. However, in 1984 it was discovered that AIDs is caused by the
HIV, which is transmitted by hetero- and homosexual intercourse, blood-to-blood
1

transmission, or mucosal exposure [8]. Today, over 36 million people worldwide
carry the virus, with women in the developing world bearing the highest burden of
infection (Figure 1).
Currently, there two types of HIV known: HIV-1 and HIV-2, with HIV-1
being more prevalent due to higher virulence [9]. Considering genetic variability,
HIV-1 can be further divided into three groups: major (M), outlier (O), and new
(N) [10]. Currently, HIV-1 group M is the most prominent group and can be
further divided by subtypes (clades). These clades, designated A-K, vary in
incidence depending on location. In North America, clade B predominates,
whereas in Africa clade C is the most common form of infection [11]. This sheer
genetic variability of HIV, more thoroughly discussed in [12, 13], contributes to
the challenges in curing HIV.
Despite the plethora of HIV subtypes, all viral particles share the same
general structure. At its genetic and structural levels, each HIV particle is
comprised of two single stranded RNAs enclosed within a capsule comprised of
p24 proteins [14]. Proteins such as reverse transcriptase and integrase are also
enveloped within the capsule, which contains glycoproteins 120 (gp120) and 41
(gp41). These two glycoproteins comprise the viral envelope (Env) protein and
are essential for cellular infection.
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Figure 1. A heat map depicting the prevalence of HIV infection. The developing
world is afflicted by higher rates of infection. Additionally, women in these areas
are more susceptible to infection. Image taken from the World Health
Organization’s website [15].
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HIV utilizes gp120 and gp41 to infect cells expressing the CD4 receptor as
well as chemokine receptor 5 (CCR5) or chemokine receptor type 4 CXCR4)
[16]. Once inside the body, HIV selectively targets CD4 T-helper cells, dendritic
cells, macrophages, as well as Langerhans cells. Broadly, the envelope
glycoproteins bind to the CD4 receptor [17] causing a conformational change in
the virus envelope. This conformation triggers additional binding to either CCR5
or CXCR4 co-receptors [18, 19], leading to viral fusion with the cell. Once inside,
the viral proteins and RNA appropriate the cellular machinery to rapidly begin
producing additional viral particles.
Like AIDS, genital herpes is also caused by viral infection. This infection is
caused by HSV, of which there are two types. HSV-2 generally results in genital
infection with corresponding symptoms; whereas HSV-1 results in oral
manifestations. More rarely, HSV-1 may infect the genital area. Currently, over
530 million people worldwide live with HSV-2 infection [20]. This high number of
infections is attributed to the virus’s ability to infect surface epithelial cells, while
producing often asymptomatic and latent infections within neuronal cells.
At its core, each HSV-2 virion is comprised of a capsid that contains
double stranded DNA [21]. Unlike HIV, the capsid only encodes viral DNA; the
host’s cellular machinery provides the means for producing additional viral
particles. The (capsule) is comprised of proteins that form an icosahedral shape,
surrounded by a lipid bilayer that forms the viral envelope. The lipid bilayer
contains a variety of surface glycoproteins, five of which are essential for binding
and entry to host cells: gB, gC, gD, gH, and gL [22, 23].
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While HSV-2 initially infects epithelial cells, post-infection the virus
anteroretrograde transports to infect neuronal ganglia, providing a reservoir for
latent infection. Entry into a cell is facilitated by viral glycoproteins gB and gC,
which non-specifically bind to heparan sulfate [24], a proteoglycan found on the
surface of host cells. These attachment points induce viral “surfing” to the cell
surface where gD facilitates receptor-mediated cell binding and internalization
[21].

After this binding event, gD interacts with a receptor and changes

confirmation to mediate fusion of the viral envelope with the cell membrane. The
conformational change is stabilized by both gB and the gH-gL dimer, which play
a critical role in viral entry. After entry, the capsule is transferred into the cellular
nucleus, where viral DNA is transcribed by the cellular machinery.
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CURRENT HIV AND HSV-2 THERAPEUTICS
Since isolating HIV in 1983, there has been a monumental effort
worldwide to prevent, treat, and cure infections. Zidovudine (or azidothymidine,
AZT), a dideoxynucleoside reverse transcriptase inhibitor (NRTI), was the first
drug approved by the Food and Drug Administration (FDA) to treat HIV in 1987
[25]. However, low tolerance, antiviral resistance, and incomplete replication
inhibition hampered the success of Zidovudine as a stand-alone drug. It is
currently used in combinational highly active antiretroviral therapy (HAART)
against HIV. Since the introduction of AZT, dozens of new therapeutics have
been introduced to combat the AIDs pandemic.
Today, there are a variety of drugs that have since been developed and
are widely available to treat HIV. These drugs are categorized based on their
mechanism of action. Currently there are six types of anti-HIV agents:
nucleoside/nucleotide

reverse

transcriptase

inhibitors

(NRTIs),

non-

nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs), protease
inhibitors (PIs), fusion inhibitors, co-receptor inhibitors, and integrase inhibitors
[26]. Nucleotide and nucleoside reverse transcriptase inhibitors (such as AZT)
are compounds that directly interact with the binding site of the viral reverse
transcriptase enzyme to inhibit virus replication. Non-nucleotide/nucleoside
reverse transcriptase inhibitors also work to inhibit reverse transcriptase
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but do not act on the enzyme’s catalytic binding site. Protease inhibitors, similar
to the previous classes, act against HIV after the virus has entered the cell. PIs
inhibit HIV protease to prevent the formation of mature viral proteins. In contrast,
fusion inhibitors act to prevent HIV entry into the cell, by binding to and
inactivating Env proteins such as gp41. Another method to prevent viral entry is
the use of co-receptor inhibitors (such as Maraviroc), which prevent gp120 and
CD4 interaction. Finally, integrase inhibitors, much like reverse transcriptase and
protease inhibitors, work after viral infection and prevent the virus from
integrating its genetic material into the host cell DNA.
This diversity of HIV therapeutics is a result of attempts to combat HIV’s
highly mutagenic nature. Often, the administration of one compound only
temporarily hinders HIV infection, and mutation restores HIV replication
competence, leading to AIDS [27]. With this in mind, Highly Active Antiretroviral
Therapy (HAART) was introduced. With HAART, a regimen of at least three
drugs from a minimum of two different classes of drugs is administered to treat
HIV-1. Typically, several RTIs and at least one PI are administered [28, 29]. The
vast majority of these medications is taken orally to help increase user
adherence. Additionally, the different classes of agents help reduce toxicity,
relative to using drugs of the same class. With the implementation of HAART,
HIV is suppressed, increasing patient life expectancy by years.
In contrast to the variety of agents available to treat HIV, only a limited
number of therapeutics are available to treat HSV-2 [30]. The top three current
therapeutics are: Acyclovir, Valaciclovir, and Famciclovir. Acyclovir, a guanosine
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derivative, acts to specifically inhibit viral DNA polymerase activity. The drug was
one of the earliest therapeutics available to combat HSV-2. However, due to the
relatively low bioavailability of Acyclovir, the prodrug Valaciclovir was developed.
Valaciclovir possesses a bioavailability three to five times that of Acyclovir,
thereby enhancing oral delivery and efficacy [31]. The last drug, Famciclovir, is a
prodrug of Penciclovir, and possesses a similar mechanism of action as Acyclovir
but can be administered topically [32]. It is important to note that there are
currently no FDA-approved therapeutics that prevent or cure HSV. Furthermore,
latent infection, combined with frequent asymptomatic and irregular recurrences
add to the challenge of curing this disease.
Correspondingly, the challenges in HSV-2 prevention and treatment,
combined with its high global incidence and propensity for co-infections,
contribute to the challenges in preventing and curing HIV. In addition to
increasing the risk of HIV co-infections [33], the asymptomatic nature of HSV
infection contributes to the lack of awareness of infection, and subsequent coinfections [34]. Even for asymptomatic cases of HSV-2 infection or latent
activation, viral loads are present with increased inflammatory and immune cell
infiltrates. In more severe cases of infection and reactivation, the genital lesions
caused by HSV-2 significantly increase the likelihood of HIV transmission via
epithelial tears [35]. With these challenges, multipurpose platforms that prevent
both HSV-2 and HIV infections are critically needed.
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ORAL AND TOPICAL PrEP
Despite the numerous antivirals available to treat HIV and HSV-2, to date
there are no agents that completely prevent or cure these infections. In terms of
prevention, pre-exposure prophylaxis (PrEP) has enabled high-risk individuals to
prevent HIV-1 infection by taking oral medication each day. However, to date,
only two compounds Tenofovir (TFV) and Emtricitabine (combined with TFV in
Truvada), are approved for PrEP by the FDA [36].
Oral PrEP has demonstrated success in preventing HIV in clinical trials
and is becoming increasingly acknowledged as a successful prevention platform
[37, 38]. By frequent administration of oral antiretroviral (ARV) compounds, such
as TFV and Emtricitabine, prevention rates of up to 62% have been achieved in
clinical trials [39, 40]. Clinical trials such as the Centers for Disease Control and
Prevention CDC 4243 and CDC 4940, and the International AIDS Vaccine
Initiative IAVI E001 and IAVI E002, demonstrate the potential effectiveness of
oral PREP, by reducing HIV infection by up to 75% [41]. However, to achieve
these levels of protection, frequent administration and strict user adherence are
critical. This was validated in the VOICE (MTN-003) clinical trial, in which oral
PrEP (and topical microbicide gels) failed to provide any meaningful protection
due to a lack of user adherence [42]. In addition to user adherence, additional
challenges of oral PrEP, based on the administration of ARVs, include renal and
bone toxicity; associated decreases in condom use; the development of antiviral
9

resistance; and reduction of drug concentration via first pass metabolism [42].
Thus new strategies are urgently needed to provide safe, effective, and long-term
protection against multiple STIs.
Given the disadvantages of oral PrEP, several topical PrEP strategies
have been developed that provide localized protection to overcome these
limitations. Topical PrEP eliminates first-pass hepatic clearance, while providing
localized doses that result in more efficacious delivery of active agents to the
local infection site [43]. These localized doses also have the effect of potentially
reducing drug toxicity. Additionally, by acting at the site of infection, topical PrEP
improves the ability of active agents to exert their effect upon incoming virus. The
potential of topical PrEP was demonstrated in the CAPRISA-004 clinical study,
where a topical gel containing TFV was used to effectively reduce HIV
transmission by 39% [44].
While traditionally topical PrEP has been administered in the form of gels,
topical PrEP delivery vehicles also include films, tablets, and intravaginal rings
(IVRs). Antiviral gels have the potential to confer adequate protection when
frequently applied. However in the MTN-003 (Voice) clinical trials, gels containing
TFV required strict user adherence in administration both prior to and after
sexual intercourse to maintain effectiveness [43, 45]. The strict dosing needed to
maintain protection resulted in suboptimal user adherence which led to
decreased protection against infection. In addition, some users experience
discomfort or leakiness, which may further reduce user acceptance and
adherence. Intravaginal films have also demonstrated protection against STIs;
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however, burst release of incorporated agents is a frequent concern [45]. Indeed,
the rapid and complete release of the encapsulated agents within hours of
administration remains a major hurdle of this technology for long-term
administration [46, 47]. User adherence is another common concern of films, with
reports of difficulty of administration as well as localized irritation after prolonged
contact [45, 48]. Vaginal tablets, another topical technology, offer a cost effective
platform to rapidly release antivirals. However, tablets suffer from the same
concerns as films, exhibiting transient activity and a lack of long-term release
[49].
In comparison to the previous technologies, intravaginal rings (IVRs)
provide the gold standard for sustained-release and have demonstrated longterm protection against STIs for up to 4 months [50, 51]. IVRs have been utilized
for over a decade, particularly for hormonal contraceptive delivery. The
translation of IVRs into HIV PrEP has been recently demonstrated in the ASPIRE
(MTN-020) clinical trial, where HIV infection was reduced by 27% for up to one
month with Dapivirine encapsulated IVRs [52]. However, concerns remain
regarding the lack of complete protection provided in clinical trials, and their
ability to incorporate less stable agents, such as biologics, due to the high
processing temperatures utilized during the manufacturing process [53]. Lastly,
user adherence of IVRs remains another major concern. In the ASPIRE trial,
women most vulnerable to infection (ages 18-21) were less likely to adhere to
IVR application [52], suggesting that alternative dosage forms may prove
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beneficial to better address women’s’ preferences and needs for protection;
improve user adherence; and achieve increased efficacy.
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ELECTROSPUN FIBERS
Relative to the existing technologies of gels, films, and IVRs, electrospun
fibers (EFs) provide a promising alternative for prolonged and localized agent
delivery, with the potential to protect against multiple STIs. Some of the
advantages of electrospun fibers include high loading efficiency to increase local
concentration, enhanced agent stability relative to administration of free agent,
and tunable sustained-release imparted by material choice. Biodegradable
polymers, such as poly(lactic-co-glycolic acid (PLGA) and poly(caprolactone)
(PCL) (Figure 2), are approved by the U.S. Food and Drug Administration (FDA)
for therapeutic use, indicating their proven biocompatibility and potential for
translation [54]. Furthermore, due to the variety of polymers available, virtually
any compound can be incorporated, and delivery durations can be altered to suit
the specific delivery requirements of a topical delivery vehicle [55, 56].
Additionally, EFs have the potential to simultaneously deliver co-incorporated
compounds including biologics such as proteins and oligonucleotides, as well as
traditional antiviral drugs [57-59]. These attributes make polymeric EFs an
attractive platform for multipurpose drug delivery against STIs.
Over the past decade, researchers have begun to incorporate antiviral
agents into polymeric EFs to prevent HIV infection. One of the first studies to
utilize electrospun fibers to combat HIV, developed pH-responsive fibers that
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encapsulated cellulose acetate phthalate (CAP) [60]. The affinity of CAP for the
HIV surface protein gp120 directly neutralizes HIV. While CAP EFs exhibited
long-term stability in low pH environments characteristic of the female
reproductive tract, the EFs quickly degraded with the introduction of semen, to
release active CAP and neutralize HIV particles. Later research by the same
group utilized polystyrene and polypropylene fibers to bind to and inhibit HIV [61].
In

this

latter

study,

fibers

were

surface-modified

with

poly(allylamine

hydrochloride) or dextran sulfate sodium to confer a positive or negative charge
to the fibers. Both surface-modified EFs inhibited HIV infection with higher
efficacy than unmodified fibers alone.
In addition to pH-sensitive and surface-modified fibers, researchers have
utilized EFs to provide tunable release of one or more incorporated active agents
for HIV-1 prevention [43-47]. The utilization of polymer blends has enabled fibers
to be finely tailored to release multiple drugs. Blends of polyethylene oxide (PEO)
and poly(L-lactic acid) (PLLA) were synthesized to encapsulate the antivirals
Maraviroc (entry inhibitor) and AZT [62]. By altering ratios of these polymers,
drug release was tailored to effectively deliver both compounds for up to several
weeks. In another study, PLGA and PCL fibers were loaded with various
concentrations of the ARV Tenofovir (TFV) [63]. These fibers demonstrated
sustained-release of TFV for 30 days as well as efficacy against HIV infection in
vitro.
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Figure 2. Chemical structure of PLGA and PCL. Both PLGA and PCL are
biodegradable polymers widely used in drug delivery research. (A) PLGA is
comprised of repeating units of glycolic or lactic acid. The addition of lactic acid
confers greater hydrophobicity to the polymer, resulting in lower degradation rate
in water. In contrast (B) poly(caprolactone) is highly hydrophobic and does not
appreciably degrade in water [64]. Lactic acid monomers may be introduced to
increase the flexibility and hydrophilicity of PCL, resulting in PLCL (poly(DLlactide-co-ε-caprolactone)). In our work, this modified derivative of PCL was
compared with PLGA for the delivery of the ARV drug, Tenofovir disoproxil
fumarate (TDF).
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Similarly, but less extensively for HSV-2, PCL matrices were fabricated
using a heat-based injection molding technique to incorporate increasing
concentrations of Acyclovir (10, 15, and 20% w/v), a potent antiviral used for
treatment against HSV-2 [65]. Encapsulated ACV exhibited release up to 30
days and retained comparable 50% inhibitory concentration (IC50) to free drug.
Further work in this field involved the use of TDF-encapsulated IVRs to protect
against HIV and HSV-2 in vitro and in vivo. Beyond demonstrating protection
against HIV and HSV-2 in vitro, these IVRs also prevented HIV infection in
macaques for up to 4 months (with monthly IVR changes) [50, 51].
Building upon this previous research, the goal of our work was to develop
PLGA and PLCL EFs containing three concentrations of the ARV prodrug TDF to
safely inhibit HIV-1 and HSV-2 infections in vitro (Figure 3). TDF was selected as
a model ARV, to demonstrate proof-of-concept of our delivery vehicles, due to its
potent efficacy against both HIV and HSV-2; its increased oral and topical
lipophilicity and cell permeability; and enhanced IC50 (by 160-fold) relative to its
prodrug counterpart, TFV [50]. Here we fabricated both PLGA and PLCL EFs to
evaluate and compare two different biodegradable polymers known to impart
sustained-release of active agents. In this work we synthesized 3 different
formulations for each polymer, PLGA and PLCL, and we characterized the
loading and sustained-release of TDF from EFs. We subsequently assessed the
efficacy of fiber release eluates against HSV-2 and HIV-1 infection in vitro for up

16

to 4 weeks. We additionally demonstrated the biocompatibility of these EFs in
vaginal keratinocytes, ectocervical cells, and endocervical cells.
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Figure 3. Structure of Tenofovir disoproxil fumarate (TDF). TDF, a prodrug of
Tenofovir (TVF), was developed to enhance oral bioavailability and efficacy. Both
TDF and TFV are classified as potent NRTIs; however, TDF has an over 160-fold
lower IC50 compared to TFV in vivo [50]. Newer derivatives of TFV such as
Tenofovir alafenamide (TAF) are currently being researched to impart even
greater efficacy.
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MATERIALS AND METHODS
Materials
Poly(lactic-co-glycolic acid) (PLGA 50:50, 0.55-0.75 dL/g, 31-57k MW)
and poly(DL-lactide-co-ε-caprolactone) (PLCL 80:20, 0.75 dL/g, 37k MW) were
both purchased from Lactel Absorbable Polymers (Cupertino, CA). Solvents 1, 1,
1, 3, 3, 3—hexafluoro-2-propanol (HFIP) and trifluoroethanol (TFE) were
obtained from Fisher Scientific (Pittsburgh, PA). TDF was purchased as Viread®
(Tenofovir disoproxil fumarate, Gilead Sciences Inc., Foster City, CA) tablets
from the University of Louisville Pharmacy. Other chemicals, including dimethyl
sulfoxide (DMSO) and Thiazolyl Blue Tetrazolium Bromide (MTT) were
purchased from Sigma Aldrich (St Louis, MO). Fetal bovine serum (FBS),
antibiotics (penicillin/streptomycin and gentamicin), Minimum Essential Medium
(MEM), Keratinocyte Serum-free Medium (KSFM), and Dulbecco’s Modified
Eagle Medium (DMEM) were purchased from VWR and Thermofisher. Simulated
vaginal fluid (SVF) was prepared in house using a previously established
protocol [66].

Cell Lines and Virus
TZM-bl cells were obtained from the NIH AIDS Research and Reference
Reagent Program (ARRRP). These cells are a genetically engineered HeLa cell
clone that expresses CD4, CXCR4, and CCR5 and contain Tat-responsive
19

reporter genes for firefly luciferase (Luc) and Escherichia coli β-galactosidase
under regulatory control of an HIV-1 long terminal repeat [67, 68]. TZM-bl cells
were maintained in Gibco Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) containing 10% heat-inactivated FBS, 25 nM HEPES, and 50 µg/mL
gentamicin, in a vented T-75 culture flask. Env-pseudotype HIV was kindly
provided by Dr. Nobuyuki Matoba from the University of Louisville. To conduct
HSV-2 plaque assays, African green monkey kidney (Vero E6) cells and HSV-2
(4674) were kindly provided by Dr. Kenneth Palmer from the University of
Louisville. Cells were maintained in MEM supplemented with 10% FBS, penicillin
(100 µg/mL), and streptomycin (100 µg/mL).
To assess cytotoxicity, Endocervical, End1/E6E7 (End1); ectocervical,
Ect1/E6E7 (Ect1); and vaginal keratinocyte, VK2/E6E7 (VK2) cell lines were
used (courtesy of Dr. Kenneth Palmer). These cell lines were selected because
they are representative of the cell types in the female reproductive tract that
would be exposed to the topical EFs. End1, Ect1, and VK2 cells were maintained
in KSFM supplemented with bovine pituitary extract (50 µg/mL), epidermal
growth factor (0.1 ng/mL), penicillin (100 µg/mL), and streptomycin (100 μg/mL).
The media was further supplemented with calcium chloride (CaCl2) to a final
concentration of 0.4 mM. During cell trypsinization for plating and cell count, cells
were

neutralized

using

DMEM/F12

(Gibco)

Penicillin/Streptomycin.

Synthesis of Electrospun Fibers
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with

10%

FBS,

and

1%

PLGA and PLCL EFs were prepared with different solvents and TDF
concentrations spanning (1-20% wt drug/wt polymer (w/w)). Blank fibers
containing no TDF were prepared as negative controls. For blank EFs, 15-20%
PLGA w/w and 12-20% PLCL w/w were dissolved in either 3 mL TFE or HFIP
solvent overnight while shaking at 37 °C. The following day, 2 mL of PLGA or
PLCL solution was aspirated into, and electrospun from a 3 mL plastic syringe on
a custom built device housed in an air-filtered Plexiglas chamber. All formulations
were electrospun with a flow rate of 2.0 mL/hr and an applied voltage of 20 kV.
EFs were collected on a rotating 4 mm outer-diameter stainless steel mandrel,
located 20 cm from the blunt needle tip. Sample flow rate was monitored by an
infusion pump (Fisher Scientific, Pittsburgh, PA) and the voltage was applied
using a high voltage power supply (Spellman CZE 1000R). For fibers
incorporating TDF, 1, 10, or 20% w/w TDF was dissolved in 1.2 mL solvent
overnight. The next day the TDF solution was added to 1.8 mL polymer solution
prior to electrospinning. After electrospinning, fibers were removed from the
mandrel and dried overnight in a desiccator cabinet.

Electrospun Fiber Size and Morphology
The impact of various parameters including: solvent choice, polymer
composition, and TDF concentration on fiber size and morphology were
evaluated using scanning electron microscopy (SEM). Desiccated EFs were
placed on carbon tape, sputter coated with gold, and imaged using SEM (Supra
35 SEM Zeiss). SEM images were acquired at magnifications ranging from
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1,000-5,000x to enable clear visualization of the fiber microstructure. The
average fiber diameter was determined by analyzing SEM images in NIH
ImageJ, and drawing line elements across a minimum of 50 fibers per image.
Statistical significance between fiber diameters was determined using the Tukey
post hoc t-test (p < 0.05).

Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled
Release
Incorporated TDF was quantified by dissolving 5 mg of PLGA and PLCL
EFs in 1 mL of (1 M) NaOH overnight. TDF in the supernatant was measured
using UV absorption spectroscopy at 260 nm (Synergy HT Biotek) in UV
transparent 96-well plates. Quantification was performed using a TDF standard
diluted in NaOH, with blank fibers as background correction. TDF values
determined from absorbance measurements were compared with the quantity of
TDF added prior to electrospinning to obtain percent encapsulation efficiency
(EE), where EE = [(Mass of TDF Incorporated)/(Mass of TDF Initially Added)] x
100. Unless otherwise noted, all samples were analyzed in triplicate.
Controlled release experiments were performed to assess the release of
TDF from EFs. Triplicate 10 mg fiber pieces were cut and suspended in 1 mL of
simulated vaginal fluid (SVF) to represent intravaginal conditions in vitro.
Samples were incubated at 37 °C and constantly shaken. The complete volume
of SVF was removed and replaced with fresh SVF at time points: 1, 2, 4, 6, 24,
48, 72 hr, and 1, 2, 3, and 4 wk. Statistical significance of both loading and
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release profiles between fiber formulations were determined by one-way ANOVA
with the Bonferroni post hoc t-test (p < 0.05)

In Vitro Efficacy of PLGA and PLCL Fibers against HIV-1 infection
HIV pseudovirus assays were used to assess the efficacy of TDF released
from EFs against HIV infection in vitro. TZM-bl cells were infected with Envpseudotype HIV, kindly provided by both Dr. Nobuyuki Matoba (University of
Louisville) and the NIH AIDS Research and Reference Reagent Program
(ARRRP). To produce and propagate HIV Env-pseudovirus, HEK293T/17 cells
were transfected with two plasmids, one containing an Env-defective HIV
genome and a plasmid solely expressing Env. Transfection was facilitated with
the use of FuGENE (Promega). HEK293T cells were allowed to incubate for 48
hr, after which viral particles were collected and titered using the 50% Tissue
Culture Infectious Doses assay (TCID50). Viral particles were stored at -80 °C
until use [69].
To determine the in vitro efficacy of PLGA and PLCL TDF EFs against
Env-pseudotype HIV infection, TZM-bl cells were seeded in 96-well plates at
100,000 cells/well in 100 µL of DMEM. Fifty microliters of fiber eluate media
(DMEM 10% FBS) collected from time points: 1 and 24 hr; week 1; week 2
(release from days 7-14), week 3 (release from days 14-21), and week 4 (release
from days 21-28) were diluted by a maximum of 5 orders of magnitude from
collected eluate (1:100,000 maximum dilution). Eluate dilutions were added to
cells in triplicate, and 50 µL of diluted virus stock (1:8) was subsequently added
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to each well. The administered virus dose resulted in relative luminescence units
(RLU) of at least twenty times that of background (untreated/uninfected cells),
yielding an average maximum of 100,000 RLUs in our experiments. Three
controls

were

used

in

the

experiment:

untreated/uninfected

cells,

untreated/infected cells, and blank fiber eluate-treated/infected cells. For wells
containing untreated/uninfected and untreated/infected cell controls, 100 µL
DMEM was added to the wells; for infected cells with blank fiber eluate, 50 µL
DMEM was added to 50 µL blank fiber eluate. After infection, plates were
incubated 48 hr at 37 °C. After incubation, 100 µL of media was removed from
each well and replaced with 100 µL of Bright Glo Reagent (Promega). Cells were
incubated at room temperature for another 5 minutes and the luminescence of
each well was read. The amount of virus inhibition was determined by
normalizing the RLUs of infected treated cells to untreated/infected cells.
Additionally, all RLU values were corrected by subtracting the RLU of
untreated/uninfected cells. IC50 values were determined using GraphPad 6.0
sigmoidal regression analysis. Unless otherwise noted, all experiments were run
with three or more replicates per treatment group. Statistical significance
between the IC50s was determined using one-way ANOVA with the Bonferroni
post hoc t-test.

In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection
HSV-2 plaque assays were conducted to test the efficacy of TDF EFs
against HSV-2 infection in vitro. Fibers were incubated in 10 mL complete plating
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media (1% FBS MEM) for 1 and 24 hr. Additional fiber eluates were collected at
week 1; week 2 (release from days 7-14); week 3 (release from days 14-21); and
week 4 (release from days 21-28) to assess the ability of PLGA and PLCL TDF
EFs to provide prolonged delivery and corresponding HSV-2 protection. The
antiviral activity of PLGA and PLCL TDF EF eluates was determined using HSV2 (4674) plaque assays in Vero E6 cells. Vero E6 cells were seeded at 600,000
cells/well and grown to near confluence for 24 hr in a 6-well flat bottom plate.
After 24 hr, the media was removed and cells were simultaneously administered
2 mL of fiber eluate serial dilutions from the above collected time points and
3,000 PFU of HSV-2 per well. Free TDF was used as a positive control for HSV-2
inhibition, in parallel with untreated/uninfected cells; whereas untreated/infected
cells were used as a positive control of cell infection and death. After 48 hr, cells
were fixed with methanol for 10 min, stained with 0.1% crystal violet for 30 min,
and washed with DI water. Plaques were counted, and plaque numbers from
experimental groups were normalized relative to the number of plaques in
untreated/infected cells (~280-300 plaques). Samples were analyzed in triplicate,
and GraphPad was used to determine the IC50 values of the TDF EF
formulations. Statistical analysis was performed by comparing the average
percent inhibition of HSV-2 using one-way ANOVA with the Bonferroni post hoc ttest.

In Vitro Cytotoxicity of PLGA and PLCL Fibers
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Vaginal epithelial (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical
(End1/E6E7) cells were incubated with TDF EFs in KSFM to assess the in vitro
biocompatibility of TDF fibers. Cells were plated at a density of 300,000 cells/well
in 12-well plates and incubated in triplicate with 1 mg fiber pieces placed in
transwell inserts (1 mg/mL final concentration). No treatment (media alone) and
10% DMSO were used as positive and negative controls of cell viability,
respectively. After 24, 48, and 72 hr incubation, 10 mL of MTT reagent was
added to the cells, cells were lysed, and absorbance was read at 570 nm the
following day. PLGA and PLCL EF-treated cell absorbance values were
normalized to untreated cell absorbance to obtain percent viability.

26

RESULTS
Electrospun Fiber Size and Morphology
Fiber morphology was evaluated using SEM, and ImageJ software was
used to assess fiber diameters. Figure 4 shows blank PLGA and PLCL fibers
fabricated using either HFIP or TFE solvent. For fibers electrospun in HFIP, 15%
w/w PLGA or 12% w/w PLCL provided well-defined fiber morphologies. However
with TFE, both polymers required an increase in concentration to 20% (w/w) to
produce well-delineated microstructures. The average diameters were 2.0 ± 0.8
and 1.7 ± 0.4 µm for 15% PLGA and 12% PLCL fibers made with HFIP, and 1.9
± 0.9 and 1.9 ± 0.8 µm for 20% PLGA and 20% PLCL fibers made with TFE.
Once well-delineated fibers were established, the effect of TDF incorporation on
PLGA and PLCL EF morphologies electrospun with HFIP was evaluated (Figure
5).
The morphologies and diameters of TDF EF formulations are shown in
Figures 5 and 6, respectively. Prior to TDF incorporation, the average diameters
of all blank fiber formulations were similar, ranging from 1.7 to 2.0 µm, with no
statistical significance observed between formulations (Figure 6A). In
comparison, fibers incorporating TDF showed a random distribution of fiber
diameters for PLGA; whereas for PLCL, a decreased trend in fiber diameter was
observed. The average fiber diameters for HFIP 15% PLGA 1%, 10%, and 20%
TDF were 1.1 ± 0.3, 0.7 ± 0.2, and 1.1 ± 0.4 µm. For HFIP 12%
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PLCL 1%, 10%, 20% TDF fibers, the resulting fiber diameters were 1.1 ± 0.5, 0.9
± 0.3, 0.7 ± 0.2 µm, with PLCL fibers demonstrating a decrease in fiber diameter
between blank (no TDF) and TDF-incorporated formulations. Additionally, TDF
incorporated fibers electrospun with TFE solvent, displayed a similar decrease in
diameters to 1.2 ± 0.4 µm and 0.6 ± 0.2 µm, for PLGA and PLCL respectively. All
TDF fiber diameters had statistically different diameters relative to blank PLGA
and PLCL EFs. However, no statistical significance was observed between the 1,
10, and 20% TDF fiber formulations as a function of TDF incorporation.
Additionally, there was no statistical difference in diameter between TDF
incorporated PLGA and PLCL fibers. Thus any addition of TDF resulted in
decreased fiber diameter relative to blank fibers; whereas additional TDF
incorporation had no significant effect on fiber diameter.
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Figure 4. SEM images of blank PLGA and PLCL fibers electrospun using
different solvents. (A) 15% w/w PLGA in HFIP; (B) 20% w/w PLGA in TFE; (C)
12% w/w PLCL in HFIP; and (D) 20% w/w PLCL in TFE. Scale bars represent 10
µm.
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Figure 5. SEM images of PLGA and PLCL fibers prepared with increasing
concentrations of TDF (1%, 10%, 20% w/w), using HFIP as solvent. (A) Blank
PLGA, (B) 1% TDF, (C) 10% TDF, and (D) 20% TDF PLGA fibers; (E) Blank
PLCL, (F) 1% TDF, (G) 10% TDF, and (H) 20% TDF PLCL fibers. Scale bars
represent 10 µm.
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Figure 6. Average diameters of electrospun fibers measured from SEM images,
using ImageJ. (A) Diameters of blank PLGA and PLCL fibers electrospun with
either HFIP or TFE solvents. Diameters ranged from 1.7 to 2.0 m. No statistical
significance was observed between fiber diameters prepared with either HFIP or
TFE. (B) Diameters of TDF-incorporated EFs were significantly smaller than
blank fiber counterparts, ranging from 0.7 to 1.2 m (TFE data not shown). While
the PLGA TDF fiber diameters seemed randomly distributed, PLCL TDF fibers
demonstrated a trend of decreased diameter with increasing TDF concentration.
While statistical significance was observed between blank fibers and all TDF fiber
formulations, no statistical difference in diameters was observed between the
TDF EF formulations.
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Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled
Release
To determine the loading of TDF in PLGA and PLCL EFs, fibers and
unincorporated TDF were weighed and dissolved overnight in (1M) NaOH. Serial
dilutions of TDF in NaOH were used to create a standard curve (Figure 7). The
linear range of the standard curved extended from 1 mg/mL to 488 ng/mL of
TDF. All concentrations of TDF (1, 10, and 20% w/w) fibers and standards were
measured via absorbance at 260 nm. Table 1 summarizes the total loading (µg
TDF/mg fiber) and encapsulation efficiency (EE) achieved for the various fiber
formulations. Overall, we observed that fibers electrospun with HFIP resulted in
high EEs spanning 43-75%. The 10% TDF PLGA and PLCL fibers electrospun
with HFIP solvent were compared to 10% TDF PLGA and PLCL fibers
electrospun with TFE, to assess the loading difference based on electrospinning
solvent choice. Whereas the 10% TDF PLGA and PLCL EFs electrospun with
HFIP showed a high encapsulation efficiency of 69% for each formulation, the
TFE EFs incorporated only 41-44% TDF. Within the HFIP electrospun fibers, the
1% TDF PLGA and PLCL fibers incorporated less than half of the added TDF,
showing the least incorporation of all formulations, while the 10% TDF fibers
demonstrated consistently high EE around 69%. The 20% TDF fibers showed
some variability in EE based on polymer type, with PLGA incorporating 56% TDF
and PLCL incorporating 76%. Since the electrospun fibers made with HFIP
showed 30% higher encapsulation than TFE fibers (for the 10% formulation), in
addition to the high polymer concentration required to fabricate well-delineated
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fibers with TFE (20% for PLGA and PLCL vs. 12 and 15% for PLGA and PLCL,
respectively), HFIP was selected to electrospin subsequent formulations.
After determining the PLGA and PLCL fiber loading, we assessed the
release of TDF from PLGA and PLCL EFs in SVF for up to 4 weeks. Standard
solutions of TDF in SVF were prepared to assess TDF release in SVF eluates
(Figure 8). Measuring absorbance at 260 nm, the standard curve ranged from
488 ng/mL to 1mg/mL of TDF. Figure 9 demonstrates increased TDF release
per mass of fiber, with increased incorporation of TDF for both PLGA and PLCL.
All fiber formulations experienced a burst release spanning 0-60% for each
formulation after 48 hr of release. Based on total percent loading, the 10% and
20% PLCL EFs showed greater burst release of 3% and 21%, respectively at 1
hr, compared to the 10% and 20% PLGA fibers (Figure 9B). However, after 24 hr
incubation, both 10% and 20% PLGA and PLCL EFs released nearly equivalent
amounts of TDF per total loading. Similarly, cumulative release of TDF per mass
of fiber showed that 10% and 20% PLCL fibers released more TDF (35 and 39
µg/mg) than corresponding PLGA fibers at 1 hr. After 24 hours, the differences in
TDF released between PLCL and PLGA fibers decreased to 29 and 7 µg/mg for
the 10% and 20% formulations, respectively.
For prolonged release after 4 weeks, PLGA fibers exhibited higher
cumulative release of incorporated TDF per mass of fiber, compared to PLCL
fibers, with the exception of the 10% TDF EFs (Figure 9A). On a percent loading
basis however, PLGA fibers consistently released more TDF than PLCL fibers for
the 1%, 10%, and 20% TDF formulations. PLGA fibers released 25, 70, and 86%
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of their cargo; whereas PLCL fibers released, 52, and 73% of their cargo for the
10% and 20% formulations after 4 wk. TDF release was not detected from the
1% PLCL formation. Furthermore, we observed an increase in release at 21 days
from all PLGA fibers, which can be attributed to polymer matrix degradation
under acidic conditions. From these experiments we observed that PLGA fibers
have the potential for increased sustained-release over a 4 week period based
on percent loading, relative to PLCL fibers which seemed to plateau after initial
burst release. However, on a mass-by-mass basis, PLGA fibers were only
slightly improved for release relative to PLCL fibers, with the exception of the
10% TDF PLGA formulation.
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Table 1.
Quantification of TDF fiber loading and encapsulation efficiency.
Loading TDF/Fiber
(µg/mg)

Encapsulation Efficiency
(% )

10 ± 0.3

45 ± 1.6

HFIP 15% PLGA 10% TDF

88 ± 3.9

69 ± 2.5

20% TDF

162 ± 1.8

56 ± 0.6

1% TDF

7 ±0.1

43 ± 0.6

HFIP 12% PLCL 10% TDF

87 ± 1.8

69 ± 1.4

20% TDF
TFE 20% PLGA 10% TDF

171 ± 3.3

75 ± 1.4

91 ± 6.5

44 ± 2.5

TFE 20% PLCL 10% TDF

98 ± 10.8

41 ± 3.7

Fiber Formulation
1% TDF

PLGA and PLCL fibers electrospun with HFIP demonstrated higher loading and
encapsulation efficiencies, relative to PLGA and PLCL fibers electrospun with
TFE. Furthermore, linear increases in encapsulation efficiency were observed
based on the amount of TDF added to PLGA and PLCL formulations.
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Figure 7. The standard curve used to quantify TDF loading and encapsulation
efficiency. Fibers and TDF standard were dissolved overnight in (1M) NaOH.
Samples and TDF standard absorbance were read at 260 nm. The initial stock
concentration of free TDF was 1000 µg/mL. Serial dilutions of 1:2 were
performed in UV 96-well plates. The limit of detection determined from this
standard curve was 0.488 µg/mL TDF, and the linear range extended from 0.488
to 1000 μg/mL TDF.
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Figure 8. The standard curve used to quantify TDF sustained-release. The free
TDF standard was diluted in simulated vaginal fluid (SVF) to quantify fiber
release eluates in SVF. Samples and TDF standard absorbance were read at
260 nm. The initial stock concentration of free TDF was 2000 µg/mL; however,
the linear range of this standard curve extended from 0.488 to 1000 μg/mL TDF.
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Figure 9. Sustained-release profiles of 1, 10, and 20% TDF PLGA and PLCL
fibers in SVF. (A) Cumulative release of TDF per milligram of fiber (µg TDF/mg
fiber) over one month. (B) Cumulative release of TDF as percent total loading
(%) over one month. While PLCL fibers showed a higher burst release after 1 hr,
overall PLGA fibers exhibited greater sustained-release over the course of 4 wk,
relative to PLCL fibers. In agreement with our previous work release of TDF from
PLGA fibers in the acidic environment of SVF increased at 21 days [70].
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In Vitro Efficacy of PLGA and PLCL Fibers against HIV-1 infection
Short-Term Efficacy
To assess the antiviral activity of TDF PLGA and PLCL fibers, HIV
inhibition assays were performed using fiber eluates collected at different
controlled-release time points. Both short- and long-term release samples were
collected to assess efficacy after different time points. For short-term (1 and 24
hr) assessment of antiviral activity, 10 mg fibers were incubated in 1 mL DMEM
for 1 or 24 hr. A histogram of the HIV inhibition after administration of the 1 hr
(Figure 10A) or 24 hr fiber release eluates (Figure 10B) is shown in Figure 10
and the corresponding IC50s are shown in Table 2. All EFs with 10 or 20% TDF
completely inhibited viral infection in TZM-bl cells down to a 1:100 dilution.
For dilutions of 1 and 24 hr eluates exceeding 1:100, viral inhibition was
more pronounced after administration of the 24 hr eluates, relative to 1 hr
eluates. The increased efficacy observed with 24 hr eluates can be attributed to
the higher amount of TDF released within 24 hr. For both time points, the PLCL
fibers seemed to impart greater protection against in vitro infection. This was
quantified by calculating the IC50 values for all PLGA and PLCL TDF fibers
(Table 2).
Overall, the antiviral activities of these eluate dilutions demonstrate that
the amount of TDF in the fiber correlates well with increased viral inhibition. For
the 1% TDF PLGA and PLCL fibers, 1 hr undiluted eluates decreased infection to
27% and 10%, relative to untreated/infected controls at 100% infection. However,
subsequent dilutions of the 1% TDF 1 hr eluates yielded decreased protection
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against HIV-1 infection. In contrast, after 24 hr release, the 1% TDF PLGA and
PLCL fibers completely inhibited virus infection, with subsequent decreases in
virus inhibition corresponding with increased eluate dilution. Full infection
resulted after administration of the 1% PLGA and PLCL fibers at a dilution of
1:10, and 1:1000, respectively for the 1 hr eluates; and 1:1000 and 1:100 for the
PLGA and PLCL 24 hr eluates.
For the 10% TDF formulations, both PLGA and PLCL fibers exhibited
complete protection against HIV down to 1:100 and 1:1000 eluate dilutions,
respectively after 1 hr. After administration of the 24 hr eluates, complete
protection was observed even after a 1:1000 dilution of each formulation.
Subsequent dilutions of PLGA eluates for 1 hr and 24 hr time points exhibited an
increase in infectivity (decrease in prevention) to 31% and 13% for 1:1000, and
complete infectivity for 1:10,000 dilutions, respectively. For PLCL, complete
protection was achieved with the 1:1000 eluate dilutions at both 1 and 24 hr time
points. Additionally, these fibers showed efficacy even at eluate dilutions of
1:10,000, with 48% and 69% infectivity at 1 and 24 hr. The corresponding IC50s
for 10% TDF PLGA and PLCL EFs were 33 and 49 ng/mL after 1 hr, and 55 and
43 ng/mL after 24 hr (Table 2).
As expected, the 20% TDF fibers exhibited the highest efficacy against
HIV infection per mass of fiber tested. Similar to the 10% TDF PLGA and PLCL
EFs, 20% TDF fibers completely inhibited infection after a 1:1000 dilution, and
exhibited partial efficacy (58-100%) between 1:10,000 and 1:100,000 dilutions.

40

The corresponding IC50s for 20% TDF PLGA and PLCL EFs were 34 and 29
ng/mL after 1 hr release, and 63 and 30 ng/mL after 24 hr release (Table 2).
Overall, the IC50s of TDF PLCL fibers were lower (more efficacious) than
the IC50s of PLGA TDF fibers for the 10% and 20% formulations at 1 and 24 hr.
The only exception was the 1 hr 10% TDF PLGA EF release eluate, which
demonstrated higher efficacy relative to PLCL EFs. In addition, the IC50s of all
TDF fiber eluates were compared to the IC50s of free TDF exposed to media for
similar durations. As shown in Table 2, all fibers demonstrated equivalent or
lower IC50s relative to free TDF (90 and 65 ng/mL at 1 and 24 hr respectively).
Although increased TDF incorporation correlated to higher protection against HIV
infection, after accounting for TDF concentration, all TDF fibers proved similarly
efficacious. There was no statistical difference between the IC50s of the different
polymer formulations at 1 and 24 hr time points of release. Additionally, no
statistical significance was found between the same fiber formulations at different
time points. Finally, there was no statistically significant difference between fiber
and free TDF IC50s, suggesting that either could be used to provide short-term
protection for 1 or 24 hr.
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Figure 10. Results from in vitro HIV-1 infection assays. PLGA and PLCL fiber
eluates inhibit HIV infection after 1 and 24 hr (A and B), and 1 and 2 wk of
release (C). Dilutions of release eluate from 10 mg/mL fiber concentrations at
different time points were normalized to untreated/infected cell control RLUs to
assess percent HIV inhibition in vitro. Figures show the percent of cells infected,
after incubation with: (A) 1 hr release eluate; (B) 24 hr release eluate; and (C) 1
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and 2 wk release eluate from 20% TDF PLGA and PLCL fibers only, compared to
(D) blank fiber eluates at each time point, and (E) free TDF (200 µg/mL) eluate
for 1 and 2 wk. After 3 and 4 wk incubation, minimal protection against HIV-1 was
shown for all fiber eluates (F). The 20% TDF PLGA fibers eluates showed no
protection even for undiluted eluates. In contrast, undiluted 20% TDF PLCL
eluates inhibited infection by 55%; however, no protection was demonstrated at
1:10 dilution.
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Table 2.
PLGA and PLCL fiber IC50s (against HIV-1) after administration of the 1 and 24
hr eluates.

PLGA 10% TDF

IC50 at 1 Hr
(ng/mL)
33 (27 to 40)

IC50 at 24 Hr
(ng/mL)
55 (46 to 67)

PLGA 20% TDF

34 (27 to 51)

63 (43 to 89)

PLCL 10% TDF

49 (39 to 60)

43 (20 to 90)

PLCL 20% TDF

29 (19 to 46)

30 (18 to 45)

Free TDF

91 (82 to 100)

65 (18 to 120)

Fiber Formulation

The IC50s of TDF fiber eluate are similar or less than free TDF (91 and 65
ng/mL). However, no statistical significance between formulations at the same
time point, within the same formulation at different time points, or between
formulations and free TDF at the same time point were observed (p > 0.05).
Confidence intervals of IC50s are shown in parentheses.
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Long-Term Efficacy
To assess the long-term efficacy of the fibers against HIV infection in vitro,
eluates were collected from 10 mg of 20% TDF PLGA and PLCL fibers after
incubation in 1 mL DMEM for 1, 2, 3, and 4 wk. Twenty percent TDF fibers were
selected due to their greater efficacy and applicability to future dosing potential in
vivo. A histogram of HIV inhibition after administration of the 1 and 2 wk fiber
release eluates is shown in Figure 10C and the corresponding IC50s are
quantified in Table 3. After 1 and 2 wk, both PLGA and PLCL EFs completely
inhibited HIV infection with no dilution. However, only the 1 wk eluates
completely inhibited HIV infection, even after a 1:100 dilution. Two week eluates
demonstrated weaker activity, showing only marginal protection (14% and 27%)
at 1:10 dilutions of PLGA and PLCL fiber eluates, respectively. The
corresponding IC50s were 60 and 350 ng/mL for 1 wk PLGA and PLCL eluates
and 18,530 and 2900 ng/mL (18.5 and 2.9 μg/mL) for 2 wk PLGA and PLCL
eluates. Free TDF controls showed a similar decrease in inhibition, relative to
their IC50s after 1 and 24 hr exposure to media (91 and 65 ng/mL), to 34,050
and 37,250 ng/mL (34 and 37.2 μg/mL) at 1 and 2 wk, suggesting the
degradation of free TDF after prolonged exposure to media (Figure 10E).
Undiluted samples from weeks 3 and 4 showed minimal protection against HIV at
the doses tested (Figure 10F).
Although PLGA showed higher efficacy (60 ng/mL), relative to PLCL (350
ng/mL) for 1 wk eluates, the IC50s between PLGA and PLCL were not
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statistically significant. However, the IC50s of both PLGA and PLCL fibers were
statistically significant compared to free TDF (p < 0.05). Furthermore, all IC50s of
the 1 wk eluates were statistically significant (p < 0.05) relative to the 1 hr, 24 hr,
and 2 wk time points. For 2 wk eluates, all samples exhibited IC50s that were
statistically different from each other. While TDF PLGA EFs demonstrated a
marked increase in IC50 after 2 wk compared to PLCL with IC50s of 18,530
ng/mL and 2,900 ng/mL (18.5 and 2.9 ng/mL) respectively, both PLGA and PLCL
EFs proved more efficacious at 1 and 2 wk than administration of free TDF.
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Table 3.
PLGA and PLCL fiber IC50s (against HIV-1) after administration of long-term 1
and 2 wk release eluates.

PLGA 1 Wk

IC50 at 1 or 2 Wk
(ng/mL)
60 (28 to 126)

PLGA 2 Wk

18530 (6609 to 51000)

PLCL 1 Wk

350 (260 to 460)

PLCL 2 Wk

2900 (1600 to 5300)

TDF 1 Wk

34050 (29710 to 39750)

TDF 2 Wk

37250 (33790 to 41070)

Fiber Formulation

As exposure time to media increased, the efficacy of TDF fibers decreased.
However, both PLGA and PLCL fiber eluates were more efficacious than free
TDF after 1 and 2 wk exposure to media. Confidence intervals of IC50s are
shown in parentheses.
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In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection
To evaluate the potential of these fibers to inhibit HSV-2 infection, the
antiviral efficacy of TDF EFs was also assessed in HSV-2 plaque assays. Due to
higher concentrations required for future in vivo work, only 20% TDF PLGA and
PLCL fibers were evaluated. Similar to the HIV infection assay, eluate from 5
mg/mL fibers at 1 and 24 hr was tested and shown to completely inhibit viral
plaque formation. Figure 11 illustrates the results of serial dilutions (1:1.5) of 1
and 24 hr eluates. Both PLGA and PLCL fiber eluates completely inhibited HSV2 infection, and exhibited decreased protection with increased dilution. Eluates
from 24 hr showed greater efficacy against HSV-2 infection due to the increased
amount of released TDF.
The IC50s of incorporated TDF from both PLGA and PLCL fibers were
assessed using these dilutions. These results (Figure 12 and Table 4) show that
the IC50s of PLGA and PLCL 1 and 24 hr eluates were comparable to the free
TDF IC50 of 16 µg/mL. While the plaque assays showed enhanced protection
across dilutions provided by PLGA EFs after 1 and 24 hr, after accounting for
fiber loading, there was no significant difference in efficacy between most of the
fiber IC50s and free TDF. The only statistical differences were found with PLGA
1 and 24 hr eluates exhibiting higher efficacy against HSV-2 relative to PLCL 1 hr
eluates.
Fiber eluates were also collected to assess HSV-2 protection after 1, 2,
and 3 wk. For these time points and fiber concentration (5 mg/mL) tested, no
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virus inhibition was observed (data not shown). Similarly, free TDF controls
showed a dramatic decrease in efficacy against HSV-2 infection by 1 wk.

49

Figure 11. Results from in vitro HSV-2 infection assays. Plaque assays were
conducted to assess the efficacy of 20% TDF PLGA and PLCL fiber eluates (5
mg/mL) against HSV-2 infection in vitro. Plaques were counted and normalized
to untreated/uninfected samples. Results demonstrate HSV-2 efficacy attained
with: (A) 1 hr and (B) 24 hr fiber eluate dilutions. TDF fibers were effective
against HSV-2 infection at 1 and 24 hr; however, at the concentration tested,
proved ineffective for all other eluate time points (data not shown).
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Figure 12. IC50 curve of HSV-2 plaque assay inhibition. The log of TDF fiber
eluate concentration is plotted against plaque numbers that have been
normalized to untreated/infected samples. Both PLGA and PLCL TDF fiber
eluates from 1 and 24 hr show similar IC50s to free TDF (~16 µg/mL).
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Table 4.
PLGA and PLCL fiber IC50s (against HSV-2) after administration of the 1 and 24
hr eluates

Fiber Formulation

IC50 (µg/mL)

PLGA 20% TDF (1 hr)

14.78 (13.25 to 16.49)

PLGA 20% TDF (24 hr)

14.95 (13.55 to 16.55)

PLCL 20% TDF ( 1 hr)

14.93 (14.42 to 15.47)

PLCL 20% TDF (24 hr)

15.35 (13.86 to 16.99)

Free TDF

15.73 (14.0 to 17.68)

Plaque assays were performed to assess the antiviral activity of 20% TDF fiber
eluates against HSV-2 infection. Fiber eluates from 1 and 24 hr showed similar
activity, relative to free TDF. However, 1, 2, 3, and 4 wk eluates were ineffective
with the dose administered, against HSV-2 infection (data not shown).
Confidence intervals of IC50s are shown in parentheses.
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Figure 13. Representative pictures from HSV-2 plaque assays using undiluted
fiber eluates. Undiluted eluates from the 24 hr release of 5 mg/mL fibers were
incubated with Vero cells and HSV-2 for 48 hr. Eluates from fibers with
increasing percent TDF exhibited greater protection against HSV-2 infection.
20% TDF PLGA and PLCL fibers completely inhibited HSV-2 plaque formation.
Control wells with untreated/uninfected cells and TDF-treated (400 μg/mL TDFinfected cells similarly showed no plaque formation. Conversely, the positive
control of HSV-2 infection − administration of eluates from blank fibers − showed
the highest number of plaques.
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In Vitro Cytotoxicity of PLGA and PLCL Fibers
Fiber cytotoxicity was assessed in VK2, Ect1, and End1 cells, using the
MTT assay. As seen in Figure 14, high cell viability was maintained after
administration of TDF fibers for 24, 48, and 72 hr. All cells demonstrated greater
than 93, 91, and 96% cell viability at 24, 48, and 72 hr respectively, for all
formulations tested. Ten percent DMSO was used as a positive control for cell
death.
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Figure 14. Cytotoxicity assessed via MTT assay. Vaginal epithelial cell lines: (A)
Ect1 E6/E7, (B) VK2 E6/E7, (C) and End1 E6/E7, were incubated with blank or
TDF PLGA or PLCL fibers (10 mg/mL) in 12-well plates. Viability was assessed
at 24, 48, and 72 hr. All cells demonstrated greater than 93, 91, and 96% cell
viability at 24, 48, and 72 hr respectively, for all formulations tested.
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DISCUSSION
There is an urgent need for new topical PrEP technologies that can confer the
sustained-release of active agents, while providing discreet and convenient
protection against STIs. The emerging technology of biodegradable polymeric
electrospun fibers offers the potential to fill this unique role. In these studies, we
evaluated two electrospun fiber delivery platforms, comprised of the polymers,
PLGA or PLCL, for their ability to prolong the release of TDF in a potential noncoital delivery vehicle, and to protect against both HIV-1 and HSV-2 infections in
vitro. Here TDF served as a model antiretroviral drug, as it is only one of two
agents approved by the FDA to prevent HIV infection. Furthermore, TDF has
demonstrated antiviral activity against both HIV-1 and HSV-2 in vivo, establishing
its versatility as a multipurpose active agent. The goal of this work was to
develop and characterize polymeric electrospun fibers to safely and efficaciously
provide protection against both HIV-1 and HSV-2 in vitro, as a multipurpose
prevention platform. For the doses tested in our studies, TDF PLGA and PLCL
fibers demonstrated enhanced protection, relative to free TDF, against HIV-1 and
HSV-2 infections for up to 2 wks.
The first goal of this study was to determine the formulation of TDF PLGA
and PLCL fibers that resulted in the most cohesive and well-defined fiber macroand microstructures. During the fabrication of blank PLGA and PLCL fibers,
several solvents were assessed. We observed that using HFIP and
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TFE solvents yielded more reproducible PLGA and PLCL fiber morphologies,
relative to dichloromethane, chloroform, and dimethylformamide (Figure 4).
These solvents also enabled the incorporation of high weight percent polymer to
solvent, which is critical to incorporating high concentrations of active agents in
polymers. Using PLGA and PLCL fibers electrospun with HFIP as our baseline
platforms, we sought to evaluate the effect of TDF incorporation on fiber diameter
(Figures 5 and 6).
Fiber diameters play a critical role in the release properties of active
agents incorporated in polymeric vehicles. Previous research has shown that
decreasing fiber diameter has been correlated to the enhanced release of active
agents. This is attributed to the increased surface-to-volume ratio, and decreased
distance necessary for encapsulate diffusion [71, 72]. In our studies, the
incorporation of TDF resulted in decreased fiber diameters relative to blank fibers
(Figure 6). The diameters of blank fibers ranged from 1.7 to 2.0 µm, whereas
TDF fiber diameters ranged from 1.1 to 0.7 µm. In fact, even for the lowest
concentration (1%) TDF fibers tested, we observed a 50% decrease in fiber
diameter. This decrease in fiber diameter may be attributed to the charge of the
active agent, and/or polymer instability resulting from these charge effects.
Correspondingly, this instability in the polymer solution may result in the polymer
traveling longer distance/duration during the electrospinning process prior to
reaching the mandrel, promoting elongation and decreased fiber diameter [73,
74]. Thus, incorporated active agents can affect the microstructural morphologies
and diameters of electrospun fibers.
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However, the incorporation of antiviral or biological agents has been
shown to affect fiber diameters in other ways. In previous studies, Tenofovir
(TFV), a compound less hydrophilic than the fumaric salt form of TFV, TDF (TFV
solubility = 1.87 mg/mL; TDF salt form (Viread, used in this study) = 13.4 mg/mL;
Tenofovir disoproxil: 0.71 mg/mL [75, 76]), was shown to slightly increase fiber
diameter, though the differences were not statistically significant [77]. In another
study, an increase in fiber diameter was seen with increased bovine serum
albumin incorporation. In this study, the increased diameter was attributed to an
increase in viscosity of the solvent solution prior to electrospinning [78]. In other
studies, the incorporation of antivirals resulted in the opposite effect on fiber
diameter. Incorporation of TFV in polyvinyl alcohol polymers resulted in slightly
smaller diameters, which was attributed to the increased instability described
above [79]. Finally, some experiments show no change in fiber diameter after
active agent incorporation. Fibers comprised of the pH-responsive CAP polymer,
incorporating TDF, showed no change in fiber diameter compared to blank fiber
counterparts [60]. The compilation of these studies highlights that a variety of
parameters including solvent choice, polymer selection, solvent-polymer
interaction, active agent characteristics, and solution viscosity can all contribute
to the differing microstructural properties of electrospun fibers.
After obtaining well-defined and reproducible EFs, we next assessed the
loading of TDF in PLGA and PLCL fibers as a function of solvent type (HFIP vs.
TFE) used in the electrospinning process. From these loading studies (Table 1),
we observed that fibers electrospun with HFIP showed higher encapsulation
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efficiencies (25% more on average), relative to fibers electrospun with TFE.
Furthermore, variations in polymer concentration were needed to obtain welldefined fiber microstructure and high loading efficiency, based on solvent type
(15 and 12% w/w for PLGA and PLCL in HFIP; 20% PLGA and PLCL in TFE),
which may be attributed to solvent used during the electrospinning process.
Despite both HFIP and TFE sharing many characteristics such as high
polarity and similar molecular structure, there are several key differences that
may impact fiber properties. First, TFE has a higher dielectric constant [26.1
(F/m)] compared to TFE [16.7 (F/m)] [80]. This increased charge capacity may
confer additional instability to TFE solvents during electrospinning, requiring
more polymer to produce well-defined fiber morphology [81]. Additionally, this
increase in dielectric constant may result in decreased TDF incorporation,
causing TDF to localize on or near the fiber surface. HFIP also possesses a
much lower boiling point (58.2°C) relative to TFE (73.6°C). Solvents with lower
boiling points tend to produce more stable fiber morphology due to complete
evaporation during electrospinning; whereas less volatile (higher boiling point)
solvents may not fully evaporate from the polymer, causing beaded morphologies
[82]. These undesirable properties, in addition to the higher polymer
concentrations required to produce TFE fibers with well-defined fiber
microstructures and lower loading efficiencies, prompted us to fabricate all
subsequent formulations with HFIP.
Controlled release studies using TDF EFs yielded several interesting
results (Figure 9). First, as expected with most polymeric delivery vehicles, all
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PLGA and PLCL fibers demonstrated a burst release of TDF during the first 24
hr. The exception was 1% TDF fibers, which released amounts below our limit of
detection. On average, 0-60% of total incorporated TDF was released by EFs
within the first 2 days. Overall, the 10% and 20% TDF PLCL fibers showed a
higher burst release at 1 hr, based on total percent loaded, compared to
corresponding 10% and 20% TDF PLGA fibers. However, after 24 hr, PLGA and
PLCL formulations released roughly the same percent of total TDF loaded.
Based on TDF released per mass polymer, both the 10% and 20% PLCL fiber
released more TDF at 1 and 24 hours compared with PLGA EFs. As observed in
our studies, burst release in nanoscale delivery systems is a common
phenomenon due to high concentrations of drug localizing on the polymer
surface [83] . In particular, surface localization may be exacerbated during the
electrospinning process, due to charge effects between the incorporated drug,
polymers and solvent. Solution instability during electrospinning due to these
charge effects, as well as hydrophilic interactions between the solvent and drug
can also result in agent localization near the fiber surface [74, 84]. Because of
the increased hydrophobicity of PLCL, a higher percentage of TDF may have
accumulated on the fiber surface, allowing for higher burst release within the first
1 hr.
In contrast, we observed that all PLGA fibers released higher percentages
of TDF compared to PLCL fibers, after long-term incubation (4 wk) in SVF. On
average, PLGA released 20% more of the total incorporated TDF compared to
PLCL after 4 wk. We attribute this increased long-term TDF release to PLGA
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being more hydrophilic than PLCL. The increased hydrophilicity of PLGA allows
for enhanced aqueous solution penetration into the fiber, resulting in increased
diffusion of TDF from the fiber into the surrounding eluant [56, 85]. We attribute
this enhanced permeability to water, to the higher amount of TDF released from
PLGA fibers after the initial burst release phase.
In addition to the burst and diffusion release phases, we also noted
enhanced release of TDF from all PLGA and the 20% PLCL fibers around 21
days, with PLGA exhibiting the greatest enhancement in release. On average,
the 20% TDF PLGA and PLCL fibers released 7.2% and 4.8% of TDF between
the 2 and 3 wk time points, compared to only 3.7% and 0.6% released between 1
and 2 wk respectively. This enhanced release correlates with the second stage of
polymer degradation, when matrix degradation enables the release of additional
encapsulated drug.
Other studies using similar polymers yielded equivalent controlled release
results. In one recent study, TFV was incorporated in PLGA and PCL polymers
and polymer blends, and controlled release was evaluated for 10 days [63].
Similar to our work, PLGA demonstrated greater overall release of drug while
showing an initial lower burst release. In contrast, PCL released all incorporated
TFV after 24 hours, while PLGA released only ~20% of incorporated drug during
this time. Similar burst release of TDF was also observed with 20:80 PCL:PLGA
fibers, a trend that differed from the prolonged release observed from polymer
blend incorporation of TFV [63]. Furthermore, several formulations of PCL/PLGA
blends were fabricated, demonstrating decreased burst release of TFV with
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increasing PLGA concentration [63]. We expect that similar blends may prove
suitable to tailor the release of TDF, despite its increased lipophilicity.
In another study, the antiviral compounds, MVC (Maraviroc) and AZT,
were encapsulated in PCL, polyethylene oxide (PEO), and poly-L-lactic acid
(PLLA) polymer blends. Sustained-release from 70:30 PEO/PLLA blends showed
almost complete release of hydrophilic compounds after 1 hr, due to the extreme
hydrophilicity and quick degradation of PEO. In contrast, 30:70 PEO:PLLA
blends exhibited lower burst release and higher sustained-release relative to the
more hydrophilic 70:30 PEO/PLLA blends. Additionally, the moderately
hydrophobic 30:70 PEO/PLLA fibers demonstrated better release profiles relative
to pure PCL fibers, which released around 95% of incorporated drugs after 1 hr.
This more efficacious release profile was attributed to the intermediate
hydrophobicity and crystallinity of PLLA compared to PEO and PCL [62]. The
hydrophilicity of PEO confers quick degradation in aqueous solutions, resulting in
burst release; whereas PLCL is highly hydrophobic, causing incorporated
compounds to localize on the fiber surface, also guaranteeing high burst release.
The results from these studies are in agreement with our observations that
polymers comprised of lactic and glycolic acid, relative to the more hydrophobic
PLCL, exhibit less burst release of moderately hydrophilic compounds.
Last, we compared TDF release, based on the percent TDF incorporated
(1, 10, or 20%) in the fiber. While we expected that 20% TDF fibers would
release more TDF than 1 or 10% TDF EFs, based on equal polymer mass, as a
percent of total loading, we observed that 20% TDF PLGA and PLCL fibers
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released a higher proportion of the total incorporated TDF (86% and 74%
respectively) over 4 wk, relative to 10% TDF PLGA and PLCL EFs (70% and
52%). This phenomenon may be partially due to the decreased fiber diameters
resulting from higher TDF concentrations, as exhibited by PLCL EFs. Here the
slightly smaller diameter fibers associated with increased TDF concentration may
enhance release due to a higher fiber surface area. Another possibility may be
due to the distribution of TDF within the polymer fibers. Due to the differences in
hydrophobicity between PLGA and PLCL, combined with the increased
concentration of hydrophilic/lipophilic TDF, higher proportions of the drug may
localize to the fiber surface. Thus, increased TDF concentrations per mass of
fiber, may also contribute to higher burst release, corresponding with our
observations
After characterizing these fibers, TDF EFs were evaluated for their
potential to protect against HIV and HSV-2 infections in vitro (Figures 10-13). In
these studies, TDF EF eluates of up to 2 wk, conferred protection against HIV,
particularly for the 10 and 20% formulations (Figure 10); whereas HSV-2
inhibition was only achieved using the 1 or 24 hr release eluate (Figure 11). One
factor that we believe contributes to this lack of efficacy associated with longer
release times is the difference in TDF potency against HSV-2 and HIV-1. While
TDF is efficacious against both HSV-2 and HIV-1, TDF is much less efficacious
for HSV-2 (IC50 = 16 µg/mL) relative to HIV (0.06 µg/mL). Based on the release
profiles of the 20% TDF PLGA and PLCL polymers, we expect that we would
need approximately 15-20 mg fiber to provide 1 mg of TDF release (over one
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month), and corresponding efficacy after 2 wk release. To account for this and in
concurrent work, correspondingly increased amounts of TDF fibers will be used
to assess HSV-2 efficacy after longer durations of fiber release. These estimates
are within the dosing we envision for in vivo studies, in which similar studies have
delivered a range of 0.2 to 0.7 mg/mL TDF per day within the murine
reproductive tract to prevent HIV/HSV-2 infections [50, 51].
In addition to the increased TDF concentration needed to prevent HSV-2
relative to HIV-1 infections, the duration of fiber exposure to eluate likely impacts
the potency of TDF released from the fibers. This is clearly observed in our
efficacy studies where the administration of 1 and 24 hr TDF fiber eluates
demonstrated similar efficacy to free TDF; whereas, after 1 wk of release, TDF
fiber eluates exhibited greater efficacy against HIV-1, relative to free TDF (Tables
2 and 3). Moreover, after 2 wk, the IC50s of both TDF eluates and free TDF
increased; with the potency of free TDF more dramatically affected (Table 3).
One factor validating the improved IC50s of TDF fibers, relative to free
TDF with respect to time, is that TDF is known to crystallize and degrade in
aqueous environments both in vitro and in vivo [50, 85-87] . While, increasing the
stability of active agents is a benefit of utilizing delivery platforms such as fibers,
even TDF fibers exhibited decreased efficacy against HIV-1 after 1 to 2 wk in
eluate (Table 3). Relative to each other, PLGA fibers showed a more rapid
decrease in efficacy relative to PLCL fibers. This may be attributed to an
increase in polymer hydrophilicity with corresponding release of TDF from PLGA
fibers (Figure 9), leading to longer drug exposure in the aqueous environment.
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Additionally, long-term incubation of PLGA releases lactic and glycolic acid,
resulting in a localized decrease in pH. Correspondingly, acidic conditions are
known to enhance TDF degradation and may contribute to the decreased
efficacy of TDF incorporated in PLGA fibers [87]. Thus, the longer an
incorporated drug remains within the polymer under physiological pH, the longer
it will retain efficacy. For future work this suggests that utilization of a different
polymer or polymer blends may more optimally maintain active agent activity for
durations exceeding 1 wk. Finally, the safety of both TDF PLGA and PLCL fibers
was assessed after administration to vaginal and cervical cells. Our studies
demonstrate that all cell lines had greater than 91% viability after fiber
administration from 1 to 3 days (Figure 14). This is in agreement with our
expectations; given that both polymers and TDF are FDA-approved (PLCL is a
derivative of the FDA-approved polymer PCL). Based on these in vitro results,
we expect to see similar safety profiles from fibers in tissue mimic and in vivo
testing. This high biocompatibility, sustained-release, and demonstrated efficacy
of PLGA and PLCL fibers warrant their investigation in immunological,
pharmacokinetic/dynamic (PK/PD), and efficacy studies in vivo.
In parallel with advancing these formulations for in vivo study, our
laboratory currently seeks to enhance the efficacy of our electrospun fibers
against multiple STIs. Other polymer formulations are currently being evaluated
to enhance sustained-release properties of antivirals and biological agents. The
use of different solvents (or combination of) might confer enhanced loading of
drugs of interest. However, more importantly, different polymers or polymer
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blends might reduce the initial burst release of incorporated products while
simultaneously optimizing long-term release. Furthermore, the development of
multilayered and coaxially-spun fibers may also provide a platform suited for the
delivery of multiple compounds with sustained-release profiles. Finally, surface
modification of fibers or nanoparticle incorporation might offer alternative
avenues to enhance or complement the prophylactic potential of these fibers.
Another potential route to complement the efficacy of our fibers is the
incorporation of active agents with other mechanisms of action. The
incorporation of novel non-ARV agents may avert some of the effects of toxicity
and antiviral resistance recognized as impediments to long-term ARV use. One
promising biologic that may fulfill the needs of safety and potency against
multiple STIs is the antiviral lectin, griffithsin (GRFT), which has previously
demonstrated efficacy against both HIV-1 and HSV-2. Furthermore, GRFT can
be covalently bound to the fiber surface, acting as an adhesive scaffold to bind to
and inactivate virus, in addition to its sustained-release potential. While more
challenging, the incorporation of short interfering RNAs (siRNAs) may provide
genetically-targeted mechanisms to inhibit viral and/or host targets, such as
CCR5, to further enhance protection, while minimizing off-target effects. The
incorporation of GRFT and other biologics in EFs highlights the seemingly
limitless potential of EFs as novel topical delivery vehicles for microbicide
applications.
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SUMMARY AND CONCLUSIONS
There is an urgent need to develop new and alternative sustained-release
technologies to prevent HIV-1 and HSV-2 infections. To address these needs, we
fabricated PLGA and PLCL electrospun fibers, and compared the loading and
sustained-release properties of these fibers, using TDF as a model antiviral. Both
PLGA and PLCL fibers exhibited sustained-release for up to 4 weeks and
provided complete protection against both HIV-1 and HSV-2 infections in vitro.
Both short- (1 and 24 hr) and long-term (1 and 2 wk) protection were achieved
against HIV-1; whereas short-term protection (due to fiber dosing) was achieved
against HSV-2 in vitro. Additionally, TDF fibers demonstrated significantly
enhanced efficacy against HIV-1, relative to free TDF, after long-term release of
1 and 2 wk. Lastly, vaginal and cervical cells exposed to TDF PLGA and PLCL
fibers showed high viability, after up to 3 days administration, demonstrating their
safety in vitro.
Comparing the attributes of PLGA and PLCL TDF EFs, PLGA initially
appears to be a more promising candidate compared to PLCL, based on its
improved sustained-release profile. PLGA possesses a lower burst release as
well as increased long-term release of TDF relative to PLCL. However, upon
further investigation, PLCL EFs maintained the stability of TDF for longer
durations in vitro. However, as both formulations demonstrated efficacy against
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HIV and HSV-2 in vitro, future testing may reveal both fiber formulations to be
equally efficacious in vivo.
This work serves as the foundation for our future work. Using the
information obtained here, we seek to further enhance the efficacy and delivery
duration of small molecule antivirals and biologics from EFs by utilizing a variety
of encapsulants and polymer blends. Additionally, future in vivo work with our
TDF fibers is planned to demonstrate fiber efficacy and safety in a murine model
of infection. We predict that these, or similar electrospun fibers will confer long
lasting and sustained protection against both HIV and HSV-2 infections.
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